Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(4)
Clinical Guideline
Disease Control
Hepatocellular Carcinoma
Performance Status
Subscribe
Academic
Publications
Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines
Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines,10.1007/s12094-011-0694-x,Clinical & Translational Oncology,Jaime Feliu,Javier S
Edit
Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines
BibTex
|
RIS
|
RefWorks
Download
Jaime Feliu
,
Javier Sastre
,
Joan Maurel
,
Dolores Isla
While
hepatocellular carcinoma
(HCC) is a relatively common tumour with an annual incidence in the EU of 8 cases/100,000 inhabitants, bile tract carcinoma (BTC) is much less common, with an incidence of 4 cases per 100,000 inhabitants per year. In both cases, when planning treatment it is essential to perform accurate staging, evaluate hepatic functional reserve and performance status, and obtain the opinion of the patient. The only curative treatment is surgery. However, several interventional radiological techniques can help to achieve local
disease control
and the alleviation of symptoms. In addition, sorafenib (HCC) and chemotherapy (BTC) may contribute to prolong survival in patients with disseminated disease. Therefore, the therapeutic strategy should always be discussed and planned within a multidisciplinary tumour board.
Journal:
Clinical & Translational Oncology - CLIN TRANSL ONCOL
, vol. 13, no. 8, pp. 536-544, 2011
DOI:
10.1007/s12094-011-0694-x
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
www.springerlink.com
)
(
www.springerlink.com
)
References
(13)
Randomized controlled trial of screening for hepatocellular carcinoma
(
Citations: 151
)
Bo-Heng Zhang
,
Bing-Hui Yang
,
Zhao-You Tang
Journal:
Journal of Cancer Research and Clinical Oncology - J CANCER RES CLIN ONCOL
, vol. 130, no. 7, pp. 417-422, 2004
Diagnosis and treatment of hepatocellular carcinoma
(
Citations: 14
)
Alejandro Forner
,
Carmen Ayuso
,
Maria Isabel Real
,
Javier Sastre
,
Ricardo Robles
,
Bruno Sangro
,
Maria Varela
,
Manuel de la Mata
,
Luis Marti
,
Josep M Llovet
,
Jordi Bruix
,
F. Suárez
http://academic.research.microsoft.com/io.ashx?type=5&id=10363514&selfId1=0&selfId2=0&maxNumber=12&query=
Published in 2011.
Management of hepatocellular carcinoma
(
Citations: 899
)
Jordi Bruix
,
Morris Sherman
Journal:
Hepatology
, vol. 42, no. 5, pp. 1208-1236, 2005
Hepatocellular carcinoma: a global view
(
Citations: 15
)
Ju Dong Yang
,
Lewis R. Roberts
Journal:
Nature Reviews Gastroenterology & Hepatology - NAT REV GASTROENTEROL HEPATOL
, vol. 7, no. 8, pp. 448-458, 2010
Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
(
Citations: 19
)
Alejandro Forner
,
María E. Reig
,
Carlos Rodriguez de Lope
,
Jordi Bruix
Journal:
Seminars in Liver Disease - SEMIN LIVER DIS
, vol. 30, no. 01, pp. 061-074, 2010